戻る
Gossamer Bio Inc (GOSS)価格
GOSS 株価推移チャート
GOSS 財務
Gossamer Bio Inc
$2.52
2.85%
$0.06
終値： Jan 16, 16:00:00 GMT-5
$2.59
3.16%
$0.07
アフターマーケット：Jan 16, 20:00:00 GMT-5
主要データ
前終値
$2.45
始値
$2.47
当日レンジ
$2.45 - $2.64
52週レンジ
$0.76 - $3.87
取引高
3.8M
平均取引高
3.7M
1株当たり利益(TTM)
-0.69
配当利回り
--
時価総額
$601.7M
GOSSとは何ですか？
Gossamer Bio, Inc. engages in discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company is headquartered in San Diego, California and currently employs 144 full-time employees. The company went IPO on 2019-02-08. Seralutinib, also known as GB002, is an investigational inhaled, small-molecule, platelet-derived growth factor receptor (PDGFR), colony-stimulating factor 1 receptor (CSF1R), and c-KIT inhibitor, being evaluated in a Phase III clinical trial for the treatment of PAH. Seralutinib is designed to target the mechanisms that underlie pulmonary hypertension and to be delivered to the site of disease, via dry powder inhaler. Seralutinib is being evaluated in a Phase III clinical trial for the treatment of pulmonary arterial hypertension (PAH). Inhaled seralutinib, which is designed to act on both isoforms of the PDGFR, α and β, as well as the CSF1R and c-KIT pathways.